Dolutegravir Powder CAS 1051375-16-6 Dolutegravir 99% Purity Dolutegravir

• Customization: Available
• Powder: Yes
• Customized: Customized
• Certification: GMP, ISO 9001, USP
• Suitable for: Adult
• State: Powder
• Purity: >99%
• Sample: Available
• OEM: Available
• MOQ: 1kg
• CAS: 1051375-16-6
• Keyword: Dolutegravir
• Keyword 1: Dolutegravir Powder
• Transport Package: 1kg Foil Bag /25kg Drum
• Specification: 99%
• Trademark: /
• Origin: China
• Production Capacity: 20000

Product Description

Product Description

Description

Dolutegravir (Dolutegravir, Tivicay) is a new anti-AIDS drug developed by the British pharmaceutical giant GlaxoSmithKline (GSK) and Japan's Shionogi Pharmaceutical Company (Shionogi). In July 2012, GlaxoSmithKline Pharmaceuticals and Shionoyoshi Pharmaceuticals announced the results of the Phase III clinical trial of the new AIDS drug Dolutegravir. After receiving dolutegravir and two other old-version AIDS drugs for 48 weeks, 88% of the patients' bodies The virus was successfully suppressed, and Gilead Sciences' three-in-one oral drug Atripla (Efavirenz/Emtricitabine/TenofovirDisoproxilFumarate) After that, 81% of the virus in the patient's body was suppressed. It can be seen that the dolutegravir drug of GlaxoSmithKline is slightly better. According to the researchers, in the comparison trial, due to the side effects of the drug, 10% of the patients eventually stopped taking Gilead's Atripla drug, but only 2% of the patients stopped taking GlaxoSmithKline's dolutegravir. Drugs, it can be seen that the safety of GlaxoSmithKline dolutegravir is slightly higher.

Product name	Dolutegravir
Appearance	white Powder
Specification	99%
Shelf life	2 years when properly stored

Function and Application

Dulutvir sodium salt is a second-generation HIV-1 integrase chain transfer inhibitor. Dulutvir sodium is currently in phase III clinical trials for the treatment of HIV infection. It has been shown that Dulutvir Chemicalbook sodium salt can effectively inhibit HIV replication in cells infected with inactivated PHIV lentiviral vectors (such as peripheral blood mononuclear cells (PBMC), MT-4 cells and CIP4 cells).